NGS Streamlines Biomarker Testing in Solid Tumors
According to Chen, PharmD, MS, BCOP, CPP, next-generation sequencing (NGS) improves biomarker testing and treatment planning in solid tumors.
- Experts including Traina, MD, FASCO, and Demetria Smith-Graziani, MD, MPH, discuss the benefits of NGS.
- Other notable experts such as Mark Agulnik, MD, Mrinal M. Zuckerman, MD, and Naval G. Daver, MD, share their insights.
Next-generation sequencing improves biomarker testing and treatment planning in solid tumors.
Authors include Chen, Traina, Smith-Graziani, Agulnik, and many others.
Author summary: NGS improves biomarker testing in solid tumors.